Periprosthetic Joint Infections: A Review
Jay J. Wojcik, MD
Department of Orthopaedics & Rehabilitation, The University of New Mexico Health Sciences Center,
Albuquerque, New Mexico
Corresponding Author Jay J. Wojcik, MD. Department of Orthopaedics & Rehabilitation, MSC10 5600, 1 University of New
Mexico, Albuquerque, NM 87131 (email: jay22woj@gmail.com).
Funding The author received no financial support for the research, authorship, and publication of this article.
Conflict of Interest The author reports no conflicts of interest.

ABSTRACT
Joint replacement procedures are considered some of the
most successful surgical procedures in orthopaedics. An
increased demand for these procedures is expected owing
to an aging population and improved techniques. Despite
the success of these procedures, the complications can
be devastating, especially periprosthetic joint infections.
Considerable effort has been applied toward enhancing
the understanding of the prevention, diagnoses, and
treatment of these infections. In 2018, an international
consensus meeting convened to discuss the most relevant
issues in periprosthetic joint infections and to provide
consensus based on published studies. Additionally, the
criteria for periprosthetic joint infection diagnosis have
been updated. The purpose of this review was to highlight
a few topics of interest. The collective body of research in
periprosthetic joint infections is massive and evolving, and
surgeons should be aware of developments in this area
that may improve patient care.
Keywords: Periprosthetic Joint Infection, Arthroplasty, Hip
and Knee

INTRODUCTION
In the United States, more than 1 million joint
replacements are performed annually, including an
estimate of 7 million Americans living with a hip or knee
replacement.1 The incidence of infection after primary
total knee and hip replacement is about 1% to 2%. The
average annual cost for an infected total knee can exceed
$100,000, nearly four times the cost of an uncomplicated
procedure.2 In 2009, the estimated cost to the United
States healthcare system was $566 million, which is
estimated to increase to $1.6 billion in several years.3
Infection can lead to loss of function, increase in number
of surgical procedures and hospital stays, and prolonged
antibiotic administration with subsequent side effects.
The morbidity and mortality of patients who experience a
periprosthetic joint infection can be severe. Mortality rates
can be grim, with an average of 22% at 5 years.4
Treating periprosthetic joint infections is challenging
because they can vary considerably in presentation.
The infections are usually considered to be either
acute or chronic. Acute infections are established
postoperatively by either direct inoculation or
through hematogenous seeding. Various pathogens
can cause periprosthetic joint infections. The most

common is Staphylococcus aureus but the pathogen
Staphylococcus epidermidis often presents in
indolent chronic infections. There is no perfect test
for confirming periprosthetic joint infections, and
low virulent bacteria may evade our most sensitive
detection methods. We are frequently unable to
secure a culture, which creates challenges in deciding
appropriate treatment. Complete eradication has
proven extremely difficult, and much of that difficulty
is attributed to the resilience of biofilms. Biofilms are
a complex environment composed of bacteria within
their extra cellular matrix. This adherent biofilm matrix
provides protective properties to the bacteria residing
in a sessile state, which makes both detection and
treatment difficult. Biofilm creates an intricate system
that can evade our immune system and enhance
resistance to antibiotics by more than 1000 fold.5
The magnitude of problems regarding
musculoskeletal infections has invoked international
efforts. In 2018, a group of more than 600 international
and multidisciplinary experts convened in Philadelphia
to review questions regarding musculoskeletal infection.
The Second International Consensus Meeting on
Musculoskeletal Infection aimed to provide consensus
on important topics in orthopaedic infections. Parvizi
et al6 recently redefined the diagnostic algorithm for
periprosthetic joint infections. The attention on this
topic is well deserved, but we have a long way to go.
The purpose of this article is to examine a few topics
regarding the prevention, diagnosis, and treatments of
periprosthetic joint infections.

PREVENTION
Prevention is the first line of defense and most
important step in addressing periprosthetic joint
infections. Intense effort has been made to identify
the host factors, especially modifiable factors that
predispose patients to infections. Authors have
proposed using scoring tools to help in the preoperative
selection and optimization of patients.7 Obesity is
prevalent in prospective patients, and this host factor
can notably increase complications. In regards to
infection, there appears to be a linear risk with obesity.
Surgeons may select different body mass index (BMI,
kg/m2) cutoffs; a common cutoff is 40 BMI. Patients
with a BMI above this threshold have twice the risk
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Figure 1. New scoring based definition for periprosthetic joint infection. Proceed with caution in: adverse local
tissue reaction, crystal deposition disease, slow growing organisms. CRP, C-reactive protein; ESR, erythrocyte
sedimentation rate; LE, leukocyte esterase; PMN, polymorphonuclear; WBC, white blood cell. The superscript “a”
indicates it is for patients with inconclusive minor criteria, operative criteria can also be used to fulfill definition for
periprosthetic joint infections. The superscript “b” indicates to consider further molecular diagnostics such as nextgeneration sequencing. Figure reprinted with permission from Elsevier from The Journal of Arthroplasty, Vol 33,
Parvizi J, Tan TL, Goswami K, et al, The 2018 definition of periprosthetic hip and knee infection: an evidence-based
and validated criteria, page 1312, 2018.
of developing deep infections.8 Bariatric surgical
procedures can be highly effective in weight loss,
but meta-analysis has not shown any considerable
reduction in infections.9 It is theorized that persistent
malnutrition may be largely accountable.
In addition to identifying host factors, other
preoperative measures have shown promising results
in reducing periprosthetic joint infections. Screening
for decolonization protocols and methicillin-resistant
Staphylococcus aureus (MRSA) carriers still appear to
be controversial with no conclusive evidence about
utility and cost-effectiveness. Although concerns arise,
cleansing the entire body preoperatively appears to
be effective, particularly with chlorhexidine.10,11 Using
antibiotic cement in primary total joints continues
to be controversial without conclusive evidence. In
consideration of antibiotic stewardship, its use should
likely be reserved for specific indications. One indication
of the controversy is the split vote among delegates
during the Second International Consensus Meeting
on Musculoskeletal Infection. Preoperative systemic
antibiotics is a mainstay and a recommendation by the
American Academy of Orthopaedic Surgeons; however,
novel antibiotic delivery techniques may prove to
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be more effective when delivering concentrations of
antibiotics to the tissues at the surgical site. Chin et al12
showed that administration of intraosseous vancomycin
after tourniquet inflation resulted in nearly ten times
the tissue concentrations around the knee compared
to systemic antibiotics. There is still no evidence
to support topical vancomycin at wound closure in
total joints. The evidence for its use is isolated to
retrospective spine studies.
Operating time efficiency has been shown to
decrease infection rates in several surgical fields,
but suction tips may be an overlooked source of
intraoperative contamination.13 Givissis et al13 found
that 66% of suction tips had positive cultures after
1 h of operating room time, with the predominant
bacteria being Staphylococcus aureus. It may be
reasonable to change suction tips during prolonged
surgical procedures and avoid leaving suction tips in
surgical wounds owing to risk of air contaminants.
A common risk factor for infections are allogeneic
blood transfusions. Blood transfusions have an
immunoprophylaxis effect, and a two-fold risk of
infection has been observed after one unit of transfused
red blood cells.14 Although no current research shows a

direct effect of tranexamic acid on infection reduction,
its use has recently become widespread as a safe and
cost-effective blood saving modality. In one randomized
controlled trial (RCT) of total knee arthroplasties, use
of intraarticular tranexamic acid resulted in a decreased
blood transfusion rate of 16.7% to 1.3%.15
Studies have suggested that dilute betadine solution
reduces infection during surgical wound closure. Brown
et al16 reported a reduction in primary joint infections
using a dilute 0.35% betadine wash for 3 min. Compared
to saline, the rate of infection decreased from 0.97%
to 0.15%. There are novel closure techniques in total
joint arthroplasty (TJA) but still no concrete evidence
to support one modality over others. A recent and
large RCT that investigated antimicrobial sutures
in total joint replacement showed no difference in
surgical site infection rates.17 There is some support
for occlusive silver impregnated dressings in several
studies, including one prospective RCT that described
silver dressings as an independent factor reducing
periprosthetic joint infections.18
Finally, genetics is an uncommon host factor that
may explain infections in apparently healthy individuals.
It is suggested that some patients may have subclinical
immune deficiencies. A massive population-based
study (66,000 patients with TJA) has identified
familial clustering of periprosthetic joint infections.19
Investigators identified pedigrees with excessive
clustering of periprosthetic joint infections that did
not seem attributable to other risk factors. Other
investigations have also implied genetic susceptibility.
For example, a study out of the Czech Republic
found that variations of the innate immunity protein,
mannose-binding lectin, is linked to susceptibility to
periprosthetic joint infections.20

DIAGNOSIS
Unfortunately, there is no perfect test for diagnosing
periprosthetic joint infections and this presents a
challenge. For example, culture test results can return
negative, findings of serological tests are not sensitive,
and modern synovial assays have limitations and
results can yield false-positives and false-negatives. In
2011, the Musculoskeletal Infection Society proposed
criteria to define periprosthetic joint infections.21 The
original Musculoskeletal Infection Society criteria were
an important step in standardizing the definition and
eliminating subjectivity in diagnosing periprosthetic joint
infections. In the 2013 Initial International Consensus
Meeting, these criteria were revised and recently updated
again by Parvizi et al6 in 2018. The new definition includes
some novel markers such as synovial alpha defensin and
synovial C-reactive protein (CRP). The scoring system is
now weighted, and its design makes it easier to achieve
preoperative diagnosis. When validated against an
external cohort of patients, the new criteria exhibited
improved results compared to original Musculoskeletal
Infection Society criteria with a sensitivity of 97.7% and
specificity of 99.5%.

Another indicator of periprosthetic joint infections
is alpha defensin, an antimicrobial peptide generated
by neutrophils. Alpha defensin may be the most
accurate test for detecting periprosthetic joint
infections; however, caution must be used in certain
settings. Alpha defensin is not indicated in the early
postoperative period and may yield false-positive
results for metallosis. When diagnosing periprosthetic
joint infections, Stone et al22 proposed an algorithm that
used synovial CRP in combination with alpha defensin
to reduce false-positive and false-negative rates.
Obtaining cultures is ideal in treating periprosthetic
joint infections because it allows guidance on treatment
protocols and the ability to target antibiotics. Despite
best practices, negative culture results are common.
Notably, obtaining multiple tissue samples can improve
sensitivity of growing a pathogen. Synovial fluid should
also be obtained when possible and blood culture vials
may further enhance sensitivity.23 It has been shown that
culture swabs have high false-positive rates. If implants
are removed, sonication can improve sensitivity of
cultures from 60% to 80%.24 It is suggested to incubate
cultures for longer times if low virulent pathogens
are suspected; additionally, repeating aspiration and
culture tests is suggested if initial culture findings are
negative.25
Despite our best culturing techniques, many culture
findings are negative for infection, which presents a
treatment dilemma. A novel application of genetic
sequencing may find a larger role in diagnosing
periprosthetic joint infections.26 Compared to traditional
sequencing techniques, next-generation sequencing
is a technology with reduced time and costs. Nextgeneration sequencing expands on prior polymerase
chain reaction sequencing techniques. This allows
DNA to be extracted from samples and sequenced
in automated fashion to identify present pathogens.
Furthermore, next-generation sequencing provides the
ability to identify antibiotic resistance genes and has
the potential to obtain results faster than cultures and
detect pathogens in recent antibiotic administration.
However, this technology is still in its infancy, and these
techniques have shown to be extremely sensitive at
detecting bacterial DNA—even to the point of detecting
bacterial DNA in synovial fluid of native joints.27 These
investigations may bring to light the concept of host
colonization versus true infection.

TREATMENT
The initial treatment decision for periprosthetic joint
infections is usually between implant retention or
implant exchange, either one-stage or two-stage.
Debridement, antibiotics, and implant retention
(DAIR) can be successful in some situations. Important
prognostic factors for successful DAIR include host
factors, timing of operative treatment, pathogen
involved, exchanging modular components, aggressive
debridement, and appropriate use of antibiotics.
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Several factors make DAIR appealing, including reduced
surgical morbidity to the patient and reduced cost of
treatment if successful. Reported success rates for
DAIR vary but are generally less successful than a fullcomponent explant technique.25
To enhance biofilm eradication, different antiseptics
as adjuncts to mechanical debridement have been
investigated. Antiseptics have advantages of reaching
areas of the joint that are difficult to mechanically
debride. In the era of antibiotic resistance, they may
prove to be a useful addition. Chlorhexidine, betadine,
hydrogen peroxide, detergents, acetic acid, and even
honey have been discussed in combatting biofilms;
additionally, some of these have been used in vitro
experiments and have shown chlorhexidine to be
effective in biofilm eradication.28,29 Proprietary solutions
have recently become available and are purported
to be effective in disrupting the extracellular matrix
of biofilms. In vitro studies have recorded the ability
of proprietary solutions to reduce biofilms; however,
clinical trials are still pending.30
Two-stage exchange of periprosthetic joint infections
has reported some of the highest success rates and
remains the gold standard in the United States. On
the other hand, one-stage exchange is an attractive
option and has been shown to be effective in certain
situations. The appeal of a one-stage exchange is
quicker recovery, better functional outcomes, less
surgical-related morbidity, and decreased hospital
stays and costs. However, patient selection is critical
and the ideal candidates are healthy with an identified
non-resistant organism. Currently, no RCT directly
compares one-stage to two-stage exchange. However,
when the techniques were used on total knees, a metaanalysis found similar recurrence rates of infection
at 2 years.31 Unfortunately, failure rates remain high
regardless of treatment. Ford et al32 recently reported a
reinfection rate of 27% in two-stage exchange patients
who underwent re-implantation. Sadly, many patients
never obtain a successful re-implantation and end up
deceased, living with a spacer, or undergoing salvage
procedures such as arthrodesis or amputation.
Other approaches to treating periprosthetic joint
infections have been described. Whiteside et al33
used intraarticular antibiotic infusions in a cohort
of 18 patients with MRSA prosthetic joint infections.
For 6 weeks postoperatively, all 18 patients received
intraarticular catheter infusions of vancomycin without
the addition of systemic antibiotics. Seventeen patients
were infection-free at the minimum follow-up of 27
months.
Immunoprophylaxis are vaccines that may enhance
the ability of our immune system to combat bacteria.
These are currently being investigated in treating
periprosthetic joint infections.34 Bacteria that are
multidrug resistant are effectively threatening the
era of antibiotics. Pneumococcal vaccines have been
shown to prevent meningitis from cochlear implant-
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associated infections.35 Staphylococcus aureus vaccines
have been studied, with guarded results, in patients
with cardiothoracic and hemodialysis.36,37 A novel
Staphylococcus aureus vaccine is currently under
study. The purported advantage of this vaccine is that
it targets virulent factors involved in the establishment
of infection. This multi-antigen staph vaccine has
been shown to induce an immune response in a
stage 1 clinical trial.34 There is now a stage 2 clinical
trial underway that is investigating the vaccines’
ability to prevent infection in patients undergoing
spine procedures. Additionally, studies are currently
examining another pathway that disrupts biofilms: the
utilization of biologic compounds to disrupt bacterial
communication.38 These are known as quorum-sensing
inhibitors, and these agents may be a last line of
defense in the face of antibiotic resistance.

CONCLUSION
Periprosthetic joint infections present a complex
challenge to our society. We are bound to see
more infections with the increasing number of joint
replacement procedures, which leads to staggering
patient morbidity, patient mortality, and costs to
our healthcare system. We continue to evolve our
understanding of these infections; however, bacteria are
evolving as well and antibiotic resistance is concerning.
New approaches in prevention, diagnosis, and treatment
of these infections will hopefully improve our ability to
minimize these devastating complications.
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